Treatments and diagnostics for cancers
AssigneeWayne State University
InventorsQingping Dou, Huanjie Yang, Elisabeth I. Heath
Life of this patent
Estimating the term…
Abstract
Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
Claims17
A method of monitoring an anti-cancer effect of a castration-resistant prostate cancer (CRPC) therapeutic composition comprising Galeterone and a 20S proteasome inhibitor following its administration to a subject, the method comprising:
- detecting androgen receptor (AR) cleavage product variant 7 (AR-V7), and/or Poly (ADP-ribose) polymerase (PARP) cleavage product p65 (PARP/p65) and/or p89 (PARP/p89), and/or Spectrin α2 cleavage product αll/p120 and/or αll/p150 or 150i in a sample obtained from the subject following the administration,
- wherein presence of the AR cleavage product, and/or the PARP cleavage product, and/or the Spectrin α2 cleavage product is indicative of the anti-cancer effect.
A method of monitoring an anti-cancer effect of a combination therapy comprising Galeterone and a 20S proteasome inhibitor following its administration to a subject, the method comprising:
- obtaining a biological sample from a subject following the administration;
- contacting the biological sample with at least one antibody specific for androgen receptor (AR), Poly (ADP-ribose) polymerase (PARP), or Spectrin α2;
- detecting the binding of the at least one antibody to AR cleavage product variant 7 (AR-V7), PARP cleavage product p65 (PARP/p65) and/or p89 (PARP/p89), or Spectrin α2 cleavage product all/p120 and/or all/p150 or 150i in the biological sample,
- wherein detection of at least one of the AR cleavage product, the PARP cleavage product, or the Spectrin α2 cleavage product is indicative of the anti-cancer effect.
Dependencies are inferred from the claim text.